All In MedTech

Device Trial Radar · NCT05357378

Safety and Effectiveness of the HIT Reverse HRS

Safety and Effectiveness of the Hip Innovation Technology Reverse Hip Replacement System in Primary Total Hip Arthroplasty: A Pivotal Study

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingTitle says "pivotal". Randomized with 288 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

288

Planned (sponsor's estimate)

Start

Jul 15, 2022

Primary completion

Sep 16, 2030

Study completion Sep 16, 2038

Sponsor

Lead sponsor
Hip Innovation TechnologyNot on our public-company list
Sponsor type
Industry
First posted
May 2, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 50 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if the use of the HIT Reverse Hip Replacement System is safe and effective in patients undergoing total hip replacement. We will determine whether it is safe and effective by comparing it to the control devices.

Conditions

  • Degenerative Joint Disease
  • Osteoarthritis, Hip
  • Avascular Necrosis of Hip
  • Traumatic Arthropathy-Hip

Interventions

  • Hip Innovation Technology Reverse Hip Replacement SystemDevice

    Implantation of the Investigational Device is performed using standard surgical procedures for THA, as described in the Instructions for Use (IFU). The control hip systems will be implanted in accordance with their respective IFU, which are also in line with standard surgical approaches for THA.

  • Already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.Device

    Control Arm subjects will receive one of the already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination. * DePuy Synthes CORAIL® or DePuy Synthes ACTIS™ Total Hip System in combination with DePuy Synthes PINNACLE™Complete Acetabular Hip System. * Zimmer Biomet Taperloc®, Zimmer Z1™ Cementless Femoral Hip Stem System or Zimmer Biomet AVENIR® Complete Hip System in combination with Zimmer Biomet G7® Acetabular System. * Stryker Accolade® II femoral stem in combination with Stryker Trident® II acetabular cup. * Smith \& Nephew ANTHOLOGY® Total Hip System in combination with Smith \& Nephew R3® Acetabular System

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. OHS of 36 or more at the 2-year follow-up visitTime frame: 24 months
  2. Change in OHS of 12 or more at the 2-year follow-up visit compared to baseline.Time frame: 24 months
  3. Radiologic success at the 2-year follow-upTime frame: 24 months

1 more outcomes with a free account

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Miami Institute for Joint Reconstruction

    Miami, Florida · Recruiting

  • Advent Health Hospital, Carrollwood

    Tampa, Florida · Recruiting

  • Tampa General Health / Florida Orthopedic Institute

    Tampa, Florida · Recruiting

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.